Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00176020|
Recruitment Status : Unknown
Verified August 2005 by Heidelberg University.
Recruitment status was: Not yet recruiting
First Posted : September 15, 2005
Last Update Posted : March 15, 2006
The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment, 3-way crossover. Subjects will be randomly allocated to a treatment sequence – AAB, ABA or BAA. The two treatments will be:
- Treatment A: 500 mg nicotinic acid (Niacor(R))
- Treatment B: Niacor(R) Placebo
Each trial period will last one day, there will be a wash-out period of at least 2 days between each trial period. Five to seven days after study day 1 of trial period 3 there will be a final safety examination.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: nicotinic acid||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||18 participants|
|Official Title:||Double-Blind, Randomized, Placebo-Controlled, Single-Center, 2 Treatment, 3-Way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00176020
|Contact: Brigitte Tubach, R:N:||email@example.com|
|Principal Investigator:||Gerd Mikus, MD Bsc||Department Internal Medicine VI|